2cureX Past Earnings Performance

Past criteria checks 0/6

2cureX's earnings have been declining at an average annual rate of -38.8%, while the Medical Equipment industry saw earnings growing at 2% annually. Revenues have been declining at an average rate of 22.8% per year.

Key information

-38.8%

Earnings growth rate

-29.1%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-22.8%
Return on equity-225.1%
Net Margin-1,045.8%
Next Earnings Update30 May 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How 2cureX makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2QE Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233-31260
30 Sep 234-33270
30 Jun 234-31260
31 Mar 234-29240
31 Dec 223-30230
30 Sep 224-29220
30 Jun 224-26200
31 Mar 224-25190
31 Dec 217-19180
30 Sep 2110-1590
30 Jun 2114-10100
31 Mar 2117-8110
31 Dec 2015-7120
30 Sep 2015-7230
30 Jun 2013-8220
31 Mar 2012-8210
31 Dec 1912-8200
30 Sep 1910-6180
30 Jun 1911-6180
31 Mar 1910-6170
31 Dec 188-7160
30 Sep 186-7100
30 Jun 184-670
31 Mar 184-550
31 Dec 174-340
31 Dec 163-240

Quality Earnings: 2QE is currently unprofitable.

Growing Profit Margin: 2QE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2QE is unprofitable, and losses have increased over the past 5 years at a rate of 38.8% per year.

Accelerating Growth: Unable to compare 2QE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2QE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-9.8%).


Return on Equity

High ROE: 2QE has a negative Return on Equity (-225.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.